January 21st 2022
Updated findings from the KEYNOTE-590 study confirmed the clinical benefit of the combination of pembrolizumab and chemotherapy as a treatment for patients with locally advanced and metastatic esophageal cancer.
Thomas A. Abrams, MD, discusses the rationale for the ongoing phase 1/2 COSMIC-021 trial in microsatellite stable and mismatch repair proficient colorectal cancer.
Kanwal P.S. Raghav, MBBS, MD, discusses the rationale for the ongoing phase 2 DESTINY-CRC02 trial in HER2-overexpressing metastatic colorectal cancer.
Transarterial chemoembolization combined with lenvatinib plus sintilimab was safe and effective for patients with unresectable hepatocellular carcinoma.
Lenvatinib was effective in treating patients with recurrent hepatocellular carcinoma after liver transplantation and demonstrated manageable toxicities.
Nivolumab plus chemotherapy demonstrated a durable survival benefit for patients with gastric or gastroesophageal junction cancer, according to updated findings from the CheckMate 649 trial.
Initial treatment with lenvatinib in patients with Barcelona Clinic Liver Cancer stage B2 hepatocellular carcinoma helped prolong survival.
Sintilimab plus standard-of-care chemotherapy failed to demonstrate a significant improvement in overall survival and progression-free survival vs standard-of-care chemotherapy alone but did result in an improved objective response rate in patients with metastatic or recurrent pancreatic adenocarcinoma, according to findings from the phase 3 CISPD3 trial.
The oral fluoropyrimidine derivative S-1 led to improved survival when used as adjuvant therapy compared with surgery alone in patients with biliary tract cancers.
The combination of pembrolizumab plus best supportive care elicited improved overall survival and overall response rates as second-line therapy in patients from Asia with advanced hepatocellular carcinoma.
Adagrasib monotherapy demonstrated encouraging clinical activity in patients with previously treated pancreatic ductal adenocarcinoma and other non–colorectal gastrointestinal tumors that harbor KRAS G12C mutations.
January 20th 2022
Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.
The presence of Arthrobacter and fatty acid metabolism pathways in gut microbiomes may be linked to an increased risk of skin-related adverse events in patients with advanced gastric cancer who are receiving single-agent nivolumab.
Neoadjuvant nivolumab plus ipilimumab followed by adjuvant nivolumab elicited a pathologic complete response rate of 59% in patients with resectable microsatellite instable or mismatch repair deficient oeso-gastric junction adenocarcinoma.
Fam-trastuzumab deruxtecan-nxki demonstrated a 40% reduction in the risk of death compared with standard chemotherapy in patients with HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.
Heinz-Josef Lenz, MD, FACP, discusses the rationale for the phase 2/3 CheckMate 9X8 trial in metastatic colorectal cancer.
Edmund Scott Kopetz, MD, PhD, FACP, discusses the rationale for the ongoing phase 3 BREAKWATER trial in BRAF V600E-mutant metastatic colorectal cancer.
January 18th 2022
The combination of durvalumab and tremelimumab demonstrated a significant improvement in overall survival vs sorafenib as frontline therapy in patients with unresectable hepatocellular carcinoma, according to findings from the phase 3 HIMALAYA trial.
Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer.
January 18th 2021
Single-agent pembrolizumab demonstrated durable antitumor activity among patients with treatment-naïve hepatocellular carcinoma, suggesting that the checkpoint inhibitor may have additional utility in this space, according to findings from a phase 2 trial presented during the 2021 Gastrointestinal Cancers Symposium.
